Navigation Links
Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
Date:6/3/2010

ma‚ and infectious disease. While Vice President of Clinical Research at CV Therapeutics‚ Dr. Hislop was the development leader for the company's first product, Ranexa® (ranolazine), and championed the NDA efforts for this cardiovascular compound. Prior to CVT‚ Dr. Hislop spent seven years at Proctor and Gamble as the worldwide clinical development manager for P&G's osteoporosis drug, Actonel® (risedronate sodium). He also worked at Eli Lilly and Company in the UK as a medical advisor for the endocrinology group. Dr. Hislop has a B.Sc. from University of Surrey in Medical Biochemistry and an M.D., B.S. from the University of London.

Dr. Pennington has over 25 years of experience in the pharmaceutical industry during which he was responsible for 14 NDA and BLA approvals in the United States and 10 product approvals in countries outside the US. He joined Anthera in 2007 from CoTherix, Inc. where he served as Executive Vice President and Chief Medical Officer of a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular diseases. Previously, he was Executive Vice President, Medical and Scientific Affairs and Chief Medical Officer of InterMune, Inc., a publicly-traded biopharmaceutical company focused on the development, applied research and marketing of life-saving therapies for pulmonary and hepatic diseases, and also served as Vice President of Biological and Biotechnology Clinical Development of Bayer Corporation for 11 years. Prior to entering the pharmaceutical industry, Dr. Pennington also has years of experience in academia at Harvard Medical School and the University of California, San Francisco. He attended the University of Oregon School o
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Anthera Presents Data on Varespladib at ATVB Meeting
5. Anthera Pharmaceuticals Forms Scientific Advisory Board
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Cambridge Semantics, the leading provider ... today announced that it has been named to KMWorld’s ... Knowledge Management.’ , To create the list each ... and system integrators who identify organizations dedicated to the ... information to the right people at the right time. ...
(Date:3/3/2015)... FRANCISCO , March 3, 2015  Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health.  The first resident startups have ...
(Date:3/3/2015)... MN , March 3, 2015 /PRNewswire/ - BioAmber ... company producing sustainable chemicals, today announced it has initiated ... plant located in Sarnia, Ontario , ... to take approximately five months, with the facility being ... construction to be completed in two months and it ...
(Date:3/2/2015)... MD and Fort Washington, PA (PRWEB) March 02, 2015 ... Genetics (ASHG) and ReachMD announced today ... of audio interviews designed to educate healthcare professionals on ... management. , The series features peer-to-peer interviews ... topics such as:, ,     Translational Genomics and ...
Breaking Biology Technology:Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3
... JOLLA, Calif., April 2 TorreyPines Therapeutics, Inc. (Nasdaq: ... it received a letter from the Listing Qualifications Department of ... on the Company,s stockholders, equity as reported in its Annual ... 2008, the Company does not comply with the minimum stockholders, ...
... 2 SPO Medical Inc. (OTC: SPOM),a leading developer ... devices, announced today that it has filed its Annual,Report ... 2008. , Gross revenues of ... initial sales of SPO Medical,s finger oximeter PulseOx 6000(TM) ...
... Commission grants marketing authorization for Intercell,s IXIARO, the ... and military personnel in Europe -- This final ... for Human Medicinal Products (CHMP) in December 2008VIENNA, ... announced that its new vaccine to prevent Japanese ...
Cached Biology Technology:TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements 2SPO Medical Files Annual Report for Fiscal 2008 2SPO Medical Files Annual Report for Fiscal 2008 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... University scientists have defined a hidden second option plants ... be the first step in boosting plants, nutritional value ... phenylalanine is required to build proteins and is a ... plants, including lignin, which allows plants to stand upright ...
... negative emotions they often use spatial metaphors. A happy person is ... in the dumps. Some researchers believe these metaphors are a clue ... spatial words to talk about emotional states, we also use spatial ... To test this link between vertical space and emotion, in ...
... Human Frontier Science Program Organization (HFSPO) is pleased to ... postdoctoral fellowships, career development awards and research grants. HFSP ... selection in a global competition. The names are available ... HFSP postdoctoral fellowships are given to young scientists ...
Cached Biology News:Second plant pathway could improve nutrition, biofuel production 2To remember the good times, reach for the sky 22010 Human Frontier Science Program awards announced 2
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Request Info...
Biology Products: